Does BARICITINIB Cause Bladder transitional cell carcinoma? 7 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Bladder transitional cell carcinoma have been filed in association with BARICITINIB (Olumiant). This represents 0.1% of all adverse event reports for BARICITINIB.
7
Reports of Bladder transitional cell carcinoma with BARICITINIB
0.1%
of all BARICITINIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From BARICITINIB?
Of the 7 reports.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BARICITINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does BARICITINIB Cause?
Drug ineffective (569)
Off label use (479)
Covid-19 (347)
Pulmonary embolism (288)
Rheumatoid arthritis (284)
Headache (216)
Herpes zoster (216)
Pneumonia (216)
Death (206)
Deep vein thrombosis (201)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which BARICITINIB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
BARICITINIB vs BARIUM
BARICITINIB vs BARNIDIPINE
BARICITINIB vs BASILIXIMAB
BARICITINIB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH
BARICITINIB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED